Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks

PartnershipPositive

AI Analysis

Summary

Eli Lilly expanded its partnership with Gate Bioscience with an additional $870M+ commitment to develop new drugs using Gate's Molecular Gate technology platform, adding one undisclosed target and an option for a second.

Outcome Details

Expansion of existing alliance adding one undisclosed target with option for second, $870M+ commitment

Importance:7/10

Sentiment:

0.60

partnershiplicensingMolecular Gateunmet needdrug discovery

Related Companies

$LLY

Read the original article

Published by BioSpace on October 5, 2026 3:01 PM

Read Original